Related Experiment Videos
Anthracycline drugs and MDR expression in human leukemia
E M Pogliani1, D Belotti, G F Rivolta
1Dept. of Int. Med., University of Milan, S. Gerardo Hospital, Italy.
Cytotechnology
|January 1, 1996
Summary
P-glycoprotein (P-gp) expression in acute myeloid leukemia (AML) predicts treatment outcomes. Idarubicin may overcome P-gp-mediated multidrug resistance in AML patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- P-glycoprotein (P-gp) is a key mediator of multidrug resistance (MDR) in cancer.
- Its role in de novo acute myeloid leukemia (AML) and response to anthracyclines requires further elucidation.
Purpose of the Study:
- To investigate the prognostic value of P-gp expression in de novo AML.
- To assess the efficacy of Daunorubicin (DNR) and Idarubicin (IRR) in relation to P-gp expression.
Main Methods:
- Flow cytometry using MRK16 monoclonal antibody to detect P-gp expression in 50 de novo AML patients.
- Analysis of complete remission (CR) rates and overall survival (OS) based on P-gp status and anthracycline treatment.
Main Results:
- 60% of patients were P-gp negative (Group 1), 40% were P-gp positive (Group 2).
- CR rates were significantly higher in Group 1 (80%) vs. Group 2 (45%).
- Median OS was 20 months for Group 1 and 10 months for Group 2.
- Idarubicin showed higher CR rates than Daunorubicin in P-gp positive patients (70% vs. 40%) and improved OS.
Conclusions:
- P-gp expression at diagnosis is a significant prognostic factor in AML.
- Idarubicin demonstrates potential in overcoming P-gp-mediated multidrug resistance in AML.
- P-gp status should be considered when selecting anthracycline therapy for AML patients.